Type 3 cytokines IL-17A and IL-22 drive TGF-β–dependent liver fibrosis
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Type 3 immune response defined by increased IL-22 production drives fibrosis during chronic liver injury via enhanced TGF-β signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17A exhibited similar pro-fibrotic activity in both animal studies and in human cells124,125”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [125]
Citations
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Reciprocal T H 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., & Cheroutre, H. (2007) · Science · doi:10.1126/science.1145697 · Cited by 1,982 · cited 3×
“3, eaar7754 (2018) 26 October 2018 12 of 15 TGF- is essential for the differentiation of both TH17 and Tregs (42) and given the reported plasticity between these two cell subsets (19), it is possible that liver inflammation mediated by TNF-, IL-1, and IL-6 indirectly promotes differentiation of Tregs into TH17 cells a…”
BackgroundInfluentialPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809 · cited 3×
“Transforming growth factor– (TGF-) signaling is the key fibrogenic signal that activates hepatic stellate cells (HSCs), the main producer of extracellular matrix in the liver, and is modulated by proinflammatory mediators such as cytokines that act on HSCs and liver immune cells (1).”
BackgroundInfluentialThe aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055 · cited 2×
“Type 2 inflammation, characterized by production of IL-4, IL-5, IL-10, IL-13, IL-25, and IL-33, is associated with reduced hepatic inflammation but correlates with progression of liver fibrosis (4).”
BackgroundTh17 and regulatory T cell balance in autoimmune and inflammatory diseases
Noack, M., & Miossec, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.12.004 · Cited by 932 · cited 4×
“The ratio between Tregs and other inflammatory cells is one of the key determinants of the progression of inflammatory diseases (18).”
BackgroundInfluentialMast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906 · cited 1×
“IL-17–producing mast cells are associated with disease progression in rheumatoid arthritis and psoriasis (40, 41), suggesting that they may have a similar function in the liver.”
BackgroundThe 3 major types of innate and adaptive cell-mediated effector immunity
Annunziato, F., Romagnani, C., & Romagnani, S. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.001 · Cited by 818 · cited 2×
“The inflammatory response can be divided into three types (2).”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 1×
“Although TH17 cells were not the principal source of IL-17 in situ, they may enhance recruitment of innate effectors through induction of proinflammatory chemokines by endothelial cells (7).”
Backgroundthe Immunological Genome Consortium, Robinette, M. L., Fuchs, A., Cortez, V. S., Lee, J. S., Wang, Y., Durum, S. K., Gilfillan, S., & Colonna, M. (2015) · Nature Immunology · doi:10.1038/ni.3094 · Cited by 641
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
“Also, inhibiting IL-22 or IL-17 production by aryl hydrocarbon receptor or RAR-related orphan receptor γ antagonists improved fibrosis [136].”
BackgroundHepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“T H 17 cells drive liver fibrosis via the production of IL-17 and IL-22, which stimulate transforming growth factor-β (TGFβ) production in the liver, enhance TGFβ signalling in HSCs, and induce the production of collagen by HSCs and pro-inflammatory cytokines by both HSCs and Kupffer cells 120–122 .”
Harrell, C., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8050467 · Cited by 501
“Hyun and coworkers highlighted the importance of microRNA (miR)-125b-bearing MSC-Exos which suppressed pro-fibrotic function of HSCs by impeding activation of Hedgehog/Smoothened signaling pathway in these cells [82].”
BackgroundInfluentialMechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
“Neutrophils and mast cells can also be a major producer of IL-17 in fibrotic liver.(41) IL-17 is a profibrogenic cytokine which stimulates HSCs to increase levels of collagen type I, a-SMA, and TGF-b by activating NF-jB and STAT3.”
BackgroundIdentification of a broadly fibrogenic macrophage subset induced by type 3 inflammation
Fabre, T., Barron, A. M. S., Christensen, S. M., Asano, S., Bound, K., Lech, M. P., Wadsworth, M. H., Chen, X., Wang, C., Wang, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8945 · Cited by 355
Self-citationTaru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
Liver fibrosis: Pathophysiology and clinical implications
Berumen, J., Baglieri, J., Kisseleva, T., & Mekeel, K. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1499 · Cited by 259
“…protects from liver injury and reduces liver fibrosis (Feng et al., 2012; Ki et al., 2010; Kong et al., 2012; Radaeva, Sun, Pan, Hong, & Gao, 2004), however other reports have suggested that IL22 is profibrogenic and its pharmacological inhibition ameliorates liver fibrosis (Fabre et al., 2018).”
BackgroundTGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer
Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 202
“90 Both IL-22 and IL-17 are associated with fibrotic liver disease and enhance responsiveness to TGF-β signaling in hepatic stellate cells, 90,91 connecting inflammation and TGF-β signaling to progression of fibrotic liver disease.”
Neutrophils in liver diseases: pathogenesis and therapeutic targets
Liu, K., Wang, F.-S., & Xu, R. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00560-0 · Cited by 176
Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responses
Kalekar, L. A., Cohen, J. N., Prevel, N., Sandoval, P. M., Mathur, A. N., Moreau, J. M., Lowe, M. M., Nosbaum, A., Wolters, P. J., Haemel, A., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw2910 · Cited by 142
Immunopathobiology and therapeutic targets related to cytokines in liver diseases
He, Y., Hwang, S., Ahmed, Y. A., Feng, D., Li, N., Ribeiro, M., Lafdil, F., Kisseleva, T., Szabo, G., & Gao, B. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00580-w · Cited by 137
“The antifibrotic effects of IL-22, which have different mechanisms, have also been observed in several studies; however, IL-22 was also suggested to be a profibrotic factor in chronic HBV infection.(265,266) It is plausible that IL-22 protects against liver fibrosis by inducing HSC Fig.”
BackgroundIL-17 in the Pathogenesis of Disease: Good Intentions Gone Awry
Majumder, S., & McGeachy, M. J. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-092536 · Cited by 146
“Increased intrahepatic IL-17A and IL-22 at biopsy is considered a signature of advanced liver fibrosis with worse prognosis (76), (77).”
BackgroundSingle-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis
Alkon, N., Bauer, W. M., Krausgruber, T., Goh, I., Griss, J., Nguyen, V., Reininger, B., Bangert, C., Staud, C. J., Brunner, P. M., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.07.025 · Cited by 126
Neutrophil–macrophage cooperation and its impact on tissue repair
Bouchery, T., & Harris, N. L. (2019) · Immunology and Cell Biology · doi:10.1111/imcb.12241 · Cited by 127
“Production of IL-17 by neutrophils was shown to activate stellate cells in the liver to release transforming growth factor beta, a major profibrogenic cytokine, resulting in the deposition of type I collagen through direct signal transducer and activator of transcription 3 activation.(10,20) Similarly, both inflammati…”
BackgroundLurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 126
“When analyzing the regression phase of a CCl4 murine fibrosis model, Jiao et al. noted a delayed regression of fibrosis and a persisting population of activated HSC when CD11c+ DCs were depleted.”
BackgroundInfluentialTwo Faces of Neutrophils in Liver Disease Development and Progression
Cho, Y., & Szabo, G. (2021) · Hepatology · doi:10.1002/hep.31680 · Cited by 97
T lymphocytes as critical mediators in tissue regeneration, fibrosis, and the foreign body response
Adusei, K. M., Ngo, T. B., & Sadtler, K. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.023 · Cited by 109
The Roles of Neutrophils in the Pathogenesis of Liver Diseases
Tang, J., Yan, Z.-J., Feng, Q., Yu, L., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625472 · Cited by 108
“On one hand, increased expression of neutrophil (and mast cells)-derived IL-17 is a common signature of advanced liver fibrosis, which upregulates the expression of TGF-β receptor in HSCs and promotes liver fibrosis, and blocking IL-17/IL-22 alleviates liver fibrosis (80).”
BackgroundHepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Lo, B. C., Shin, S. B., Hernaez, D. C., Refaeli, I., Yu, H. B., Goebeler, V., Cait, A., Mohn, W. W., Vallance, B. A., & McNagny, K. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801308 · Cited by 85
“For instance, IL-22 can directly enhance fibrosis in the liver by modulating hepatic stellate cell responsiveness to TGF-b1 (43).”
BackgroundThe aryl hydrocarbon receptor in liver inflammation
Carambia, A., & Schuran, F. A. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00867-8 · Cited by 82
The gut–liver axis in immune remodeling of hepatic cirrhosis
Guan, H., Zhang, X., Kuang, M., & Yu, J. Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946628 · Cited by 77
“Likewise, in cirrhosis, neutrophil functions are also disturbed by the dysfunctional gut–liver axis, leading to inflammation-related hepatocyte injury and IL-17-dependent HSC activation (81).”
BackgroundPeng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P.-O., Padhye, A., Konen, J. M., Ochieng, J. K., Class, C. A., Fradette, J. J., Gibson, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22875-w · Cited by 72
Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis
Yang, F., Li, H., Li, Y., Hao, Y., Wang, C., Jia, P. P., Chen, X., Ma, S., & Xiao, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108051 · Cited by 78
The spatial and temporal activation of macrophages during fibrosis
Behmoaras, J. V., Mulder, K., Ginhoux, F., & Petretto, E. G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01186-x · Cited by 86
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Ikeno, Y., Ohara, D., Takeuchi, Y., Watanabe, H., Kondoh, G., Taura, K., Uemoto, S., & Hirota, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584048 · Cited by 62
Nanotechnology in Drug Delivery for Liver Fibrosis
Gu, L., Zhang, F., Wu, J., & Zhuge, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.804396 · Cited by 73
“A study using clinical liver biopsies and animal models revealed a new profibrotic function of interleukin (IL)-17A and IL-22 in a TGFβdepend manner (Fabre et al., 2018).”
BackgroundDeciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues
Miao, H., Wu, X., Zhang, D., Wang, Y., Guo, Y. P., Li, P., Xiong, Q., & Zhao, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105316 · Cited by 56
Novel Therapeutic Targets in Liver Fibrosis
Zhang, J., Liu, Q., He, J., & Li, Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.766855 · Cited by 51
“Th22 cells, for their part, produce IL-22, which drives TGF-β-dependent liver fibrosis (Fabre et al., 2018).”
BackgroundRecent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
Synergistic anti-inflammatory effect of gut microbiota and lithocholic acid on liver fibrosis
Shao, J., Ge, T., Tang, C., Wang, G., Pang, L., & Chen, Z. (2022) · Inflammation Research · doi:10.1007/s00011-022-01629-4 · Cited by 47
“HSCs are the primary extracellular matrix (EMC) source in the liver [2].”
BackgroundZai, W., Chen, W., Liu, H., & Ju, D. (2021) · Biomedicines · doi:10.3390/biomedicines9121912 · Cited by 44
The role of interleukin-22 in lung health and its therapeutic potential for COVID-19
Fang, S., Ju, D., Lin, Y. Q., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951107 · Cited by 44
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 46
Self-citationInterleukin-17 pathways in systemic sclerosis-associated fibrosis
Ahmed, S., Misra, D. P., & Agarwal, V. (2019) · Rheumatology International · doi:10.1007/s00296-019-04317-5 · Cited by 46
IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells
Beringer, A., & Miossec, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13316 · Cited by 41
Kandeel, M. K., Morsy, M. A., Alkhodair, K. M., & Alhojaily, S. (2023) · Biomolecules · doi:10.3390/biom13081250 · Cited by 42
Gut Microbiota Regulation of AHR Signaling in Liver Disease
Wang, B., Zhou, Z., & Li, L. (2022) · Biomolecules · doi:10.3390/biom12091244 · Cited by 39
“These ambiguous aspects of AHR signaling in liver fibrogenesis [82,114] and its influence on NAFLD [6,72,78] suggest a therapeutic or preventive target.”
BackgroundPerivascular stromal cells: Directors of tissue immune niches
Sbierski‐Kind, J., Mroz, N. M., & Molofsky, A. B. (2021) · Immunological Reviews · doi:10.1111/imr.12984 · Cited by 39
Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis
Yang, C.-E., Wang, Y., Hua, M.-R., Miao, H., Zhao, Y., & Cao, G. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101662 · Cited by 36
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Particle and Fibre Toxicology · doi:10.1186/s12989-022-00483-w · Cited by 37
“It has been revealed that in the progression of liver fibrosis, IL-17A functions together with IL-22 to enhance TGF-β in hepatic stellate cells [44].”
BackgroundIL-17A in Human Liver: Significant Source of Inflammation and Trigger of Liver Fibrosis Initiation
Kartasheva-Ebertz, D., Gaston, J., Lair-Mehiri, L., Mottez, E., Buivan, T.-P., Massault, P. P., Scatton, O., Gaujoux, S., Vaillant, J., Pol, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179773 · Cited by 38
“measured cytokine release by isolated intrahepatic immune cells after several hours or even for one week of in vitro stimulation [3].”
BackgroundResultInfluentialMapping the Secretome of Dental Pulp Stem Cells Under Variable Microenvironmental Conditions
Bousnaki, M., Bakopoulou, A., Pich, A., Papachristou, E., Κritis, A., & Koidis, P. T. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10255-2 · Cited by 38
“In particular, MSC-secretome administration resulted in the alleviation of liver fibrosis by suppressing hepatic stellate cells in vivo in IL-22RA1 knockout mice [7, 8].”
BackgroundMolecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity
Honma, M., & Nozaki, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153199 · Cited by 33
Li, S., Song, F., Xu, L., Li, J., Fang, L., & Tan, H. (2020) · Aging · doi:10.18632/aging.103257 · Cited by 33
“Upon liver injury, the quiescent HSCs would be activated by the cytokines, such as interleukin-6 (IL-6) [5, 6], interleukin-17 (IL-17) [7–9] and interleukein-22 (IL-22) [8, 9], secreted from the neighboring cell types within the injured liver microenvironment, including Kupffer cells, hepatocytes, sinusoidal endotheli…”
BackgroundThe implication of neutrophil extracellular traps in nonalcoholic fatty liver disease
Fa, P., Ke, B. G., Dupre, A., Tsung, A., & Zhang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292679 · Cited by 33
Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?
Cai, X., Guillot, A., & Liu, H. (2022) · Cells · doi:10.3390/cells12010132 · Cited by 36
“, found that blocking either IL-22 or IL-17 production in a mouse model resulted in fibrosis amelioration, thus identifying a pathogenic role of IL-17 and IL-22 in driving liver fibrosis [43].”
BackgroundUhlig, M., Billig, S., Wienhold, J., & Schumacher, D. (2025) · Cells · doi:10.3390/cells14050345 · Cited by 29
“In an earlier study, Fabre et al. already introduced the term “type 3 inflammation” by pointing out common mechanisms with type 3 immunity [46].”
Antifibrotic Effect of Selenium-Containing Nanoparticles on a Model of TAA-Induced Liver Fibrosis
Varlamova, E. G., Goltyaev, M. V., Rogachev, V. V., Gudkov, S. V., Karaduleva, E. V., & Turovsky, E. A. (2023) · Cells · doi:10.3390/cells12232723 · Cited by 30
Autologous Skin Fibroblast‐Based PLGA Nanoparticles for Treating Multiorgan Fibrosis
Long, Q., Liu, Z., Shao, Q., Shi, H., Huang, S., Jiang, C., Qian, B., Zhong, Y., He, X., Xiang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202200856 · Cited by 30
Multicytokine-producing CD4+ T cells characterize the livers of patients with NASH
Woestemeier, A., Scognamiglio, P., Zhao, Y., Wagner, J., Muscate, F., Casar, C., Siracusa, F., Cortesi, F., Agalioti, T., Müller, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.153831 · Cited by 28
“Discussion By providing an unsupervised analysis, our study shows for the first time to our knowledge that the progressive inflammatory development behind the transition from NAFLD to NASH is not associated with only classical CD4+ Th cell subsets, as previously suggested (6, 30, 35, 36), but rather with a larger spec…”
MethodCellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis
Ceci, L., Gaudio, E., & Kennedy, L. L. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.005 · Cited by 31
The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies
Lücke, J., Sabihi, M., Zhang, T., Bauditz, L. F., Shiri, A. M., Giannou, A. D., & Huber, S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00854-z · Cited by 33
Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis
Wan, M., Han, J., Ding, L., Hu, F., & Gao, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.604894 · Cited by 30
Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22
Hwang, S., Hicks, A., Hoo, C.-Z., Kwon, Y. S., Cho, Y. E., Moore, J. K., & Gao, B. (2023) · Liver International · doi:10.1111/liv.15619 · Cited by 27
“24 31 Therefore, careful approach needs to be taken for the therapeutic application of IL-22.”
Dumitru, A., Matei, E., Cozaru, G. C., Chisoi, A., Alexandrescu, L., Popescu, R. C., Pundiche, M. B., Dumitru, E., Rugină, S., & Tocia, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052472 · Cited by 29
“NAFLD patients showed small intestinal bacterial overgrowth [86,87], dysbiosis [88], and abnormal gut permeability, leading to liver inflammation and fibrosis [89–91].”
BackgroundRetinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
Kartasheva-Ebertz, D., Pol, S., & Lagaye, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691073 · Cited by 25
Abdelnabi, M. N., Molina, M. F., Soucy, G., Trinh, V. Q., Bédard, N., Mazouz, S., Jouvet, N., Dion, J., Tran, S., Bilodeau, M., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.08.001 · Cited by 27
“We and others previously have shown that IL22 has a pathogenic profibrogenic function in human beings and in the CCl4 and thioacetamide models of chronic toxic liver injury.(33,34) This effect is mediated through enhancement of TGF-b signaling in HSCs in a p38 mitogen-activated protein kinase-dependent manner.”
BackgroundMethodResultSelf-citationInterleukin-24 protects against liver injury in mouse models
Wang, H.-H., Huang, J.-H., Sue, M.-H., Ho, W.-C., Hsu, Y.-H., Chang, K., & Chang, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103213 · Cited by 25
“For instance, IL-22 promotes liver fibrosis by regulating TGF-b and activating HSCs [28,29].”
BackgroundFeng, R., Cui, Z., Liu, Z., & Zhang, Y. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13007 · Cited by 23
Sciurba, J. C., Gieseck, R. L., Jiwrajka, N., White, S. D., Karmele, E. P., Redes, J., Vannella, K. M., Henderson, N. C., Wynn, T. A., & Hart, K. M. (2019) · The Journal of Pathology · doi:10.1002/path.5215 · Cited by 22
Advances in the clinical use of collagen as biomarker of liver fibrosis
Meurer, S. K., Karsdal, M. A., & Weiskirchen, R. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1814746 · Cited by 25
Th17 cells in the liver: balancing autoimmunity and pathogen defense
Taniki, N., Nakamoto, N., Chu, P., Ichikawa, M., Teratani, T., & Kanai∥, T. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00917-9 · Cited by 24
STAT6 suppression prevents bleomycin‐induced dermal fibrosis
Huang, J., Puente, H., Wareing, N. E., Wu, M., Mayes, M. D., Karmouty‐Quintana, H., Assassi, S., & Mills, T. (2023) · The FASEB Journal · doi:10.1096/fj.202200994r · Cited by 21
Yang, H., Sun, J., Yao, T., Li, Y., Xu, G., Zhang, C., Liu, X.-C., Zhou, W., Song, Q., Zhang, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.644886 · Cited by 23
“Activation of p38 could increase the Smad3 phosphorylation in hepatic fibrosis (Fabre et al., 2018).”
BackgroundDefective autophagy in CD4 T cells drives liver fibrosis via type 3 inflammation
Sayegh, R. A., Wan, J., Caër, C., Azoulai, M., Gasperment, M., Baweja, S., Chouillard, M.-A., Kandiah, J., Cadoux, M., Mabire, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59218-y · Cited by 22
The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network
Volponi, C., Gazzillo, A., & Bonavita, E. (2022) · Cancers · doi:10.3390/cancers14246151 · Cited by 24
Cross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis
Li, H., Ding, P., Peng, B., & Ming, Y. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.04.007 · Cited by 23
Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
“Th17 cells are driven toward differentiation by ROS-mediated STAT3 activation, leading to IL-17 production that stimulates HSCs and perpetuates fibrogenesis [54,72].”
Inflammatory Network of Liver Fibrosis and How It Can Be Targeted Therapeutically
Lowe, K., Tanase, C. E., Maghami, S., Fisher, L. E., & Ghaemmaghami, A. M. (2023) · Immuno · doi:10.3390/immuno3040023 · Cited by 22
Crosstalk Between Autophagy and Innate Immunity: A Pivotal Role in Hepatic Fibrosis
Chen, L., Kong, D., Xia, S., Wang, F., Li, Z., Zhang, F., & Zheng, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891069 · Cited by 20
“The immune cells and parenchymal cells secrete interleukin-1β, transforming growth factor (TGF-β), tumor necrosis factor-α (TNF-α), and other kinds of cytokines to enhance the inflammatory effect of hepatocytes and activated HSCs (Mridha et al., 2017; Fabre et al., 2018; Kakino et al., 2018).”
BackgroundType 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
Kumar, V., Hertz, M., Agro, A., & Byrne, A. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260503 · Cited by 23
Han, J., Cherry, C., Mejías, J. C., Krishnan, K., Ruta, A., Maestas, D. R., Peña, A. N., Nguyen, H. H., Nagaraj, S., Yang, B., et al. (2024) · Advanced Materials · doi:10.1002/adma.202310476 · Cited by 17
Helminth egg derivatives as proregenerative immunotherapies
Maestas, D. R., Chung, L., Han, J., Wang, X., Sommerfeld, S. D., Kelly, S. H., Moore, E., Nguyen, H. H., Mejías, J. C., Peña, A. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211703120 · Cited by 19
Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease
Patil, N. Y., Friedman, J. E., & Joshi, A. (2023) · Receptors · doi:10.3390/receptors2010001 · Cited by 19
“Blocking Il22 or Il17 production using the AhR antagonist, CH223191 resulted in reduced fibrosis [79].”
BackgroundUnraveling the hepatic stellate cells mediated mechanisms in aging's influence on liver fibrosis
Wahid, R. M., Hassan, N. H., Samy, W. M., Abdelhadi, A. A., Saadawy, S. F., El-sayed, S. F., Seada, S. G., & Mohamed, S. R. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-63644-1 · Cited by 20
Davydova, A., Kurochkina, Y. D., Goncharova, V. E., Vorobyeva, M., & Korolev, M. A. (2023) · Biomedicines · doi:10.3390/biomedicines11051328 · Cited by 16
“IL-17A Bone remodeling (stimulation of osteoclastogenesis) [45] Recruitment of myeloid cells to the site of infection [46] Participation in immune responses against extracellular fungal [47] and bacterial agents [48] Maintenance of intestinal microbiota homeostasis [49] Maintenance of the epithelial barrier in the gut…”
Chen, L., Huang, Y., Zhang, N., Qu, J., Fang, Y., Fu, J., Yuan, Y., Zhang, Q., Li, H., Wen, Z., et al. (2024) · MedComm · doi:10.1002/mco2.654 · Cited by 15
“16 Understanding how neutrophils interact with HSCs may reveal the molecular mechanisms underlying neutrophil and ECM regulation during liver fibrosis.”
BackgroundYang, W., Fang, J., Zhai, J., Qiu, C., Liang, Z., Liu, Q., & Wei, H. (2024) · BMC Medicine · doi:10.1186/s12916-024-03609-3 · Cited by 15
“Hepatic stellate cells are major drivers of liver fibrosis, and IL-17A has been shown to drive collagen formation by increasing the expression of its TGF-β receptor [18].”
BackgroundYoon, J.-S., & Lee, C.-W. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00883-0 · Cited by 14
Liu, S., Chen, P., Mohammed, S. A. D., Li, Z., Jiang, X. M., Wu, J., & Liu, S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1051100 · Cited by 14
“Furthermore, the IL-17 and VEGF signaling pathways may contribute to a decrease in HF (Kumar et al., 2016; Fabre et al., 2018; Martínez-López et al., 2019; Qiao et al., 2020; Ghanim et al., 2021; He et al., 2022).”
BackgroundOverview of CircRNAs Roles and Mechanisms in Liver Fibrosis
Wang, G., Tong, J., Li, Y.-C., Qiu, X., Chen, A., Chang, C., & Yu, G. (2023) · Biomolecules · doi:10.3390/biom13060940 · Cited by 18
“In the case of liver injury, the qHSCs are activated upon cytokine stimulation, such as interleukin (IL)-6 [14,15], IL-17 [16–18], and IL-22 [17,18] that are secreted from neighboring cells such as Kupffer cells, hepatocytes, leukocytes, and sinusoidal endothelial cells [14], and these cells can transdifferentiate int…”
BackgroundImmune Checkpoints and the Immunology of Liver Fibrosis
Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 16
New insights into BMP9 signaling in liver diseases
Jiang, Q., Liu, B., & Xu, K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04182-6 · Cited by 15
Ciolfi, C., Balestri, R., Bardazzi, F., Burlando, M., Chersi, K., Costanzo, A., Dapavo, P., Gisondi, P., Malagoli, P., Pizzolato, M., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19186 · Cited by 14
Flavonoids-based nanomedicines for the treatment of liver fibrosis: A recent progress
Harini, K. S., & Ezhilarasan, D. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105467 · Cited by 15
Üremiş, M. M., Türköz, Y., & Üremiş, N. (2024) · Drug Development Research · doi:10.1002/ddr.22174 · Cited by 11
“On the other hand, it increases ROS production and the release of growth factors in the tissue (Fabre et al., 2018).”
BackgroundCao, W., Lu, J., Li, L., Qiu, C., Qin, X., Wang, T., Li, S., Zhang, J., & Xu, J. (2022) · Transplantation · doi:10.1097/tp.0000000000004205 · Cited by 14
Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease
Bernard, J. K., Marakovits, C. N., Smith, L., & Francis, H. (2023) · Seminars in Liver Disease · doi:10.1055/a-2104-9034 · Cited by 15
Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development
Sánchez, P. S., Rigual, M. D. M., & Djouder, N. (2021) · Cancers · doi:10.3390/cancers13205045 · Cited by 13
“Conversely, IL-22 was identified as a profibrogenic cytokine by enhancing non-SMAD TGFβ1/p38 MAPK signaling in HSCs [82].”
BackgroundRole of cGAS-STING pathway in fibrotic disease
Feng, L., Zhang, F., Cao, J., & Xiong, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107971 · Cited by 15
Sun, R., Xiang, Z., & Wu, B. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.11 · Cited by 14
Li, B., Qi, X.-W., Liu, Y.-M., Yan, Y., Shan, J., Cai, X.-L., Lv, J., Zhou, X., Yu, T., & Ma, X.-M. (2022) · Immunity, Inflammation and Disease · doi:10.1002/iid3.699 · Cited by 10
“However, at the late stage of infection, high levels of IL‐17 may be closely related to liver fibrosis and cirrhosis that during chronic liver disease.(24) IL‐4, as an important anti‐inflammatory factor, can down‐regulate the effects of IFN‐γ on pathogen killing and tissue LI ET AL.”
BackgroundXu, X., Ramanujam, M., Visvanathan, S., Assassi, S., Liu, Z., & Li, L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242863 · Cited by 11
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Chen, X., Wu, C. F., Tang, F., Zhou, J., Mo, L., Li, Y., & He, J. (2025) · Advanced Science · doi:10.1002/advs.202505067 · Cited by 15
Zhao, X., Xia, H., Yang, Y., Ma, T., Lu, Y., Xie, Z., Zhou, X., Liu, J., Bao, Z., Xu, H., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.05.006 · Cited by 14
“A member of the interleukin family of cytokines, IL-17A, has been identified as a crucial inducer of fibrosis in various organ systems, including the lung, liver, kidney, heart, and skin [9 – 11].”
Li, X., Wu, J., Zhu, S., Wei, Q., Wang, L., & Chen, J. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04846-0 · Cited by 10
“In general, IFNγ/LPS/TNFα promote M1 macrophage activation (phenotypic markers: MHC II, CD86, Ly6chigh, and iNOS), while IL-4/IL-10/IL-13/TGFβ/CSF-1 stimulate M2 macrophage activation (phenotypic markers: CD206, Ly6clow, CX3CR1high, and Arg1) [17, 23, 54, 55].”
BackgroundInfluentialInterleukin-22 protects from endotoxemia by inducing suppressive F4/80+Ly6GhiLy6Chi cells population
Yu, C. J., Ling, Q., Jiao, J., Liu, J., Huang, Z., Wang, F., Sun, X., & Kong, X. (2022) · BMC Immunology · doi:10.1186/s12865-022-00511-6 · Cited by 9
“For example, studies have shown that IL-22 can promote allergic airway inflammation response in epicutaneously sensitized mice [8] and can aggravate liver fibrosis by enhancing transforming growth factor-β (TGF-β) signaling in hepatic stellate cells (HSCs) [9].”
Background
Metadata
- Authors
- Fabre, T., Molina, M. F., Soucy, G., Goulet, J.-P., Willems, B., Villeneuve, J.-P., Bilodeau, M., & Shoukry, N. H.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Caprion (Canada) (CA)
- Corresponding author
- Shoukry, Naglaa H.
- ORCID
- Venue
- Science Immunology
- Published
- 2018-10-26
- Volume
- 3
- Issue
- 28
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2898290288
- Cited by
- 155
- References
- 52
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 19 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 15 · 2019: 7 · 2018: 1
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (HEO-115696)
- Fonds de Recherche du Québec - Santé
- Canadian Liver Foundation (N/A)
- Fonds de recherche du Québec – Santé (FRQS) AIDS and Infectious Disease Network
- Canadian Network on Hepatitis C
- Novartis/Canadian Liver Foundation Hepatology Research Chair (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver fibrosis, IL-17A, IL-22, TGF-beta signaling, hepatic stellate cells, p38 MAPK, neutrophils, mast cells, IL-22RA1, aryl hydrocarbon receptor, chronic liver injury, thioacetamide, carbon tetrachloride
- MeSH terms
- Interleukin-22, Animals, Azo Compounds, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Interleukins, Liver Cirrhosis, Male, Mice, Inbred C57BL, Pyrazoles, Transforming Growth Factor beta, Mice, Knockout, Interleukin-17, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.